Scancell publishes corporate deck outlining iSCIB1+ melanoma vaccine program ahead of Phase 3 trial

  • Scancell outlined plans to start a global Phase 3 study of iSCIB1+ with ipilimumab, nivolumab in first-line advanced melanoma in H2 2026.
  • Phase 3 design: double-blind, randomized, registrational trial; 550 patients; primary endpoint progression-free survival; overall survival secondary.
  • Phase 2b SCOPE update: 77% progression-free survival at 22 months versus 43% for ipilimumab, nivolumab in CheckMate 067 cross-trial comparison.
  • Regulatory timeline: FDA IND clearance in Jan 2026; Fast Track designation in Apr 2026; potential accelerated approval decision point tied to H2 2028 PFS readout.
  • Company estimated global peak sales potential up to USD 9 billion across advanced melanoma and earlier-stage settings.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scancell Holdings plc published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.